Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...

The first patient has been dosed in the QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo’s (TSE: 4568) VANFLYTA® ...

Patients received induction chemotherapy with oblimersen, cytarabine and daunorubicin. Further doses of oblimersen and high-dose cytarabine were administered as consolidation treatment in the ...

Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical ...

However, treating patients with bendamustine/rituximab plus acalabrutinib might be preferred to either option with cytarabine. Although the results showed that the bendamustine/rituximab plus ...

Daiichi Sankyo has announced the dosage of the first subject in the randomised Phase III QuANTUM-Wild trial of oral Vanflyta ...